Fluidai

Alex Muggah, Director of the Synapse Life Science Consortium, writes about the hurdles Canadian life science companies like NERv and Allarta Life Science Inc. face when it comes to commercialization. NERv is a recipient of the SOPHIE grant, administered by SLSC, which has accelerated our commercialization efforts via strategic industry partnerships.

Read more at this link:

The many hurdles life sciences startups must overcome to commercialize Alex Muggah, director of the Synapse Consortium, explains some of the hurdles life sciences startups need to face as they move from ideas to commercialization.

NERv is very excited to announce that the Ontario provincial government has committed $559,200 through the Ontario Together Fund to support the domestic manufacturing and commercialization of our breakthrough post-operative monitoring solution!

“Ontario is proud to partner with NERv Technology Inc. to enhance Ontario’s health care system while boosting the economy.” - Victor Fedeli, Minister of Economic Development, Job Creation and Trade.

Read more about how this landmark investment will enable NERv to grow and hire local talent below:

Ontario Together Fund Supports NERv Technology’s Domestic Manufacturing • NERv Technology Through the Ontario Together Fund, the Ontario provincial government has committed $559,200 to support the domestic manufacturing and commercialization of NERv Technology’s breakthrough post-operative monitoring solutions as part of the company’s $1.118 million investment. NERv Technology Inc. i...